


## Data Snapshot

### AFME Securitisation: Q2 2017

- In Q2 2017, EUR 71.6 billion of securitised product was issued in Europe<sup>1</sup>, an increase of 91% from Q1 2017 (EUR 37.4 bn) and a decrease of 5% from Q2 2016 (EUR 75.3 bn)<sup>2</sup>
- Of this, EUR 38.7 bn was placed, representing 54% of the total, compared to EUR 16.5 bn placed in Q1 2017 (representing 44% of 37.4 EUR bn) and EUR 29.6 bn placed in Q2 2016 (representing 39% of 75.3 EUR bn)
- In Q2 2017, UK RMBS led placed totals followed by Pan European CLOs and German Auto ABS:
  - UK RMBS increased from 2.5 EUR bn in Q1 2017 to 17.3 EUR bn in Q2 2017. This included one exceptionally large transaction, Ripon Mortgages plc, at 11.9 EUR bn (of which 11.0 EUR bn was placed);
  - Pan European CLOs increased from 5.8 EUR bn in Q1 2017 to 13.2 EUR bn in Q2 2017;
  - German Auto ABS increased from no placed issuance in Q1 2017 to 2.7 EUR bn in Q2 2017.

### European placed issuance



Values in EUR bn	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017 1H
European placed	419.2	105.5	24.7	89.8	88.9	87.0	75.9	78.2	83.2	96.7	55.1
European retained	175.7	713.2	399.3	288.1	287.9	170.9	104.8	138.8	133.5	142.1	53.9
European retention (%)	30%	87%	94%	76%	76%	66%	58%	64%	62%	60%	49%
Total European	594.9	818.7	423.9	378.0	376.8	257.8	180.8	217.0	216.6	238.6	109.9
Total US	2,080.5	934.9	1,385.3	1,203.7	1,056.6	1,579.2	1,515.1	1,131.5	1620.7	1792.9	825.2

**Sources:** Bloomberg, Citigroup, Dealogic, Deutsche Bank, JP Morgan, Bank of America-Merrill Lynch, RBS, Thomson Reuters, UniCredit, AFME & SIFMA

**Notes:** (1) European volumes include transactions from all countries in the European continent, including Russia, Iceland, Turkey and Kazakhstan. European volumes include CLOs and CDOs denominated in all European currencies. (2) Volumes have been subject to periodical revision according to the available updated information.

**Disclaimer:** The AFME Securitisation Data Report (the "Report") is intended for general information only, and is not intended to be and should not be relied upon as being legal, financial, investment, tax, regulatory, business or other professional advice. Neither AFME nor SIFMA represents or warrants that it is accurate, suitable or complete and neither of AFME nor SIFMA or their respective employees or consultants shall have any liability arising from, or relating to, the use of this Report or its contents. Your receipt of the Report is subject to paragraphs 3, 4, 5, 9, 10, 11 and 13 of the Terms of Use which are applicable to AFME's website (available at <http://www.afme.eu/Legal/Terms-of-Use.aspx>) and, for the purposes of such Terms of Use, the Report shall be considered a "Material" (regardless of whether you have received or accessed it via AFME's website or otherwise).